DTIC


Also found in: Dictionary, Thesaurus, Acronyms, Wikipedia.

dacarbazine

 [dah-kahr´-bah-zēn]
a cytotoxic alkylating agent, used in antineoplastic therapy primarily for treatment of malignant melanoma and in combination chemotherapy for Hodgkin's disease and sarcomas. Unlike other alkylating agents, its primary target is not DNA; its major effect is inhibition of RNA and protein synthesis. Called also DTIC.

dacarbazine

FDA Box Warning

Give under supervision of physician experienced in cancer chemotherapy.

Hematopoietic depression is most common toxicity; hepatic necrosis has also occurred.

Drug is carcinogenic and teratogenic in animals.

Prescriber must weigh potential benefit against toxicity risk.

Action

Unclear. Thought to inhibit DNA synthesis by acting as purine analog. Also causes alkylation and may interact with sulfhydryl groups.

Availability

Injection: 100-mg and 200-mg vials

Indications and dosages

Hodgkin's disease

Adults: 150 mg/m2 I.V. daily for 5 days in combination with other drugs, repeated q 4 weeks. Or 375 mg/m2 I.V. on first day of combination therapy, repeated q 15 days.

Metastatic malignant melanoma

Adults: 2 to 4.5 mg/kg I.V. daily for 10 days, repeated q 4 weeks. Or 250 mg/m2 I.V. daily for 5 days, repeated q 3 weeks.

Off-label uses

• Malignant pheochromocytoma

Contraindications

• Hypersensitivity to drug

Precautions

Use cautiously in:
• hepatic dysfunction, impaired bone marrow function
• pregnant or breastfeeding patients
• children.

Administration

• Follow facility procedures for safe handling, administration, and disposal of chemotherapeutic drugs.
• Reconstitute with sterile water for injection according to manufacturer's directions.
• Further dilute reconstituted drug with 5% dextrose in water or normal saline solution.

Administer over 30 to 60 minutes by I.V. infusion only.

Take steps to prevent extravasation, which may cause tissue damage and severe pain.

Adverse reactions

CNS: malaise, paresthesia

GI: nausea, vomiting, dyspepsia, anorexia

Hematologic: anemia, leukopenia, thrombocytopenia, bone marrow depression

Musculoskeletal: myalgia

Skin: dermatitis, erythematous or urticarial rash, alopecia, flushing, photosensitivity

Others: flulike symptoms, fever, hypersensitivity reactions including anaphylaxis

Interactions

Drug-diagnostic tests.Platelets, red blood cells, white blood cells: decreased counts

Drug-behaviors.Sun exposure: photosensitivity reaction

Patient monitoring

Frequently monitor CBC with white cell differential and platelet count. Know that hematopoietic depression is the most common toxicity and can be fatal.
• Assess infusion site closely for extravasation.

Patient teaching

Instruct patient to immediately report pain, burning, or swelling at infusion site; numbness in arms or legs; gait changes; respiratory distress; difficulty breathing; rash; or easy bruising or bleeding.
• Advise patient to minimize GI distress by eating small, frequent servings of healthy food and drinking plenty of fluids.
• Tell patient he'll undergo regular blood testing during therapy.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests and behaviors mentioned above.


dalfampridine

Ampyra


Pharmacologic class: Potassium channel blocker

Therapeutic class: Multiple sclerosis agent

Pregnancy risk category C

 

Action

Unknown. May increase conduction of action potentials in demyelinated axons through inhibition of potassium channels.

Availability

Tablets (extended release): 10 mg

Indications and dosages

To improve walking in patients with multiple sclerosis

Adults: 10 mg P.O. q 12 hours

Dosage adjustments

• Mild renal impairment

Contraindications

• History of seizures
• Moderate or severe renal impairment

Precautions

Use cautiously in:
• mild renal impairment
• pregnant or breastfeeding patients
• children younger than age 18 (safety and efficacy not established).

Administration

• Check creatinine clearance before starting drug.
• Administer with or without food.

Adverse reactions

CNS: insomnia, dizziness, headache, asthenia, balance disorder, paresthesia, seizures

EENT: nasopharyngitis, pharyngolaryngeal pain

GI: nausea, constipation, dyspepsia

GU: urinary tract infection

Musculoskeletal: back pain

Other: multiple sclerosis relapse

Interactions

None

Patient monitoring

Discontinue drug if seizure occurs.
• Monitor renal function tests regularly (especially creatinine clearance).

Patient teaching

• Instruct patient to take drug with or without food.
• Instruct patient to swallow tablet whole and not to break, crush, chew, or dissolve it.

Advise patient to discontinue drug and immediately report to prescriber if seizures occur.
• Instruct patient to promptly report urinary tract problems.
• As appropriate, review all other significant and life-threatening adverse reactions.

DTIC

5-(3,3 dimethyl-l-triazeno)-imidazole-4-carboxamide; abbreviation for dacarbazine.

DTIC

(dē′tē-ī-sē′)
n.
See Dacarbazine.

DTIC

Dacarbazine, see there.

DTIC

dacarbazine.
References in periodicals archive ?
Those who wish to receive more information about the DTIC or have any questions should call the Product and Services Branch at (703)767-8267, (DSN) 427-8267, or toll-free 1-800-225-DTIC, menu selection 6, option 1; or send an e-mail to bcorders@dtic.
DTIC Online is the gateway to unclassified, unlimited S&T information--approximately 50 percent of DTIC's collection.
DTIC Online was created specifically for the defense community and is available free at http://www.
In the Phase 2 trial (MDX010-08), 72 chemotherapy-naive patients with advanced melanoma were treated with 3 mg/kg of ipilimumab monthly for four months and were randomized to receive either ipilimumab in combination with DTIC (n=35) or ipilimumab alone (n=37).
DTIC responded to this request by launching the R & E Portal in April 2005.
BREAK-3 (BRF113683) is a phase III, randomised, open-label study comparing the efficacy, safety, and tolerability of dabrafenib to DTIC in patients with advanced (Stage III) or metastatic (Stage IV) melanoma who harbour a BRAF V600E mutation.
AMMTIAC and WSTIAC are two of the 10 DTIC Information Analysis Centers (IACs).
PTFS is uniquely qualified to support DTIC on the data warehousing contract, says John Yokley, President and CEO of PTFS.
DTIC contributes to the management, conduct and productivity enhancement of defense research and development efforts by providing access to, and transfer of, scientific and technical information for DoD personnel, DoD contractors and other U.
DTIC serves the DoD community as the largest central resource for DoD and government-funded scientific, technical, engineering and business-related information available today.
In addition to being a milestone customer, DTIC also demonstrates the innovative ways customers leverage our unified ECM platform across their organizations.
DTIC serves the Department of Defense (DoD) community as the largest central resource for DoD and government-funded scientific, technical, engineering and business-related information available today.